Lymphocyte–Monocyte Ratio Predicts the Survival in Patients With <scp>HCC</scp> Treated With Durvalumab Plus Tremelimumab

20261 citationsJournal Article

Authors

Tomomitsu Matono · Himeji Medical Center

TOSHIFUMI TADA · Himeji Red Cross Hospital

Atsushi Hiraoka · Ehime Prefectural Central Hospital

Masashi Hirooka · Ehime University

Kazuya Kariyama

Joji Tani · Kagawa University

Masanori Atsukawa · Nippon Medical School

Abstract

LMR is a readily accessible prognostic biomarker for both PFS and OS in patients with unresectable HCC treated with Dur/Tre, and may serve as a practical tool for risk stratification in clinical practice.

Topics & Keywords

Inflammatory Biomarkers in Disease Prognosis Cancer Immunotherapy and Biomarkers Immune cells in cancer

Publication Details

Published in: Liver International

Volume 46, Issue 4, pp. e70570-e70570

DOI: 10.1111/liv.70570

Field-Weighted Citation Impact: 24.23

Command Palette

Lymphocyte–Monocyte Ratio Predicts the Survival in Patients With <scp>HCC</scp> Treated With Durvalumab Plus Tremelimumab

Authors

Abstract

Topics & Keywords

Publication Details